{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:40:44Z","timestamp":1793227244705,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.neuint.2019.104583","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T11:59:18Z","timestamp":1571745558000},"page":"104583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes"],"prefix":"10.1016","volume":"131","author":[{"given":"Eman A.","family":"Elbassuoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha F.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2019.104583_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.neuropharm.2008.08.033","article-title":"Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism","volume":"55","author":"Abdin","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.104583_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.bbr.2003.12.021","article-title":"L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats","volume":"153","author":"Alam","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2019.104583_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0166-4328(02)00180-8","article-title":"Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats","volume":"136","author":"Alam","year":"2002","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2019.104583_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11064-011-0588-x","article-title":"Protection by DHA of early hippocampal changes in diabetes: possible role of CREB and NF-kappaB","volume":"37","author":"Alvarez-Nolting","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuint.2019.104583_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.neuint.2019.104583_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.freeradbiomed.2008.04.038","article-title":"Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury","volume":"45","author":"Ansari","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuint.2019.104583_bib7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist","volume":"59","author":"Arakawa","year":"2010","journal-title":"exendin-4 Diabetes"},{"key":"10.1016\/j.neuint.2019.104583_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","article-title":"Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease","volume":"136","author":"Athauda","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2019.104583_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejn.14096","article-title":"Post hoc analysis of the Exenatide-PD trial-Factors that predict response","volume":"49","author":"Athauda","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104583_bib10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2019.104583_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2019.104583_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2019.104583_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2011.77","article-title":"GLP-1 and energy balance: an integrated model of short-term and long-term control","volume":"7","author":"Barrera","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuint.2019.104583_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuint.2019.104583_bib15","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuint.2019.104583_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mds.25211","article-title":"Diabetes and risk of Parkinson's disease Movement disorders","volume":"28","author":"Cereda","year":"2013","journal-title":"Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.neuint.2019.104583_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejphar.2015.09.029","article-title":"Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease","volume":"768","author":"Chen","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.104583_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.neuint.2019.104583_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12576-014-0327-6","article-title":"Incretin attenuates diabetes-induced damage in rat cardiac tissue","volume":"64","author":"Elbassuoni","year":"2014","journal-title":"J. Physiol. Sci."},{"key":"10.1016\/j.neuint.2019.104583_bib20","first-page":"734","volume":"vol. 33","author":"Erbil","year":"2019"},{"key":"10.1016\/j.neuint.2019.104583_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1463-1326.2010.01238.x","article-title":"Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis Diabetes","volume":"12","author":"Fan","year":"2010","journal-title":"Obes. Metab."},{"key":"10.1016\/j.neuint.2019.104583_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1471-4159.2004.02399.x","article-title":"Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum","volume":"89","author":"Ferger","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2019.104583_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.neuint.2019.104583_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/IJGM.S51665","article-title":"Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies","volume":"6","author":"Gerich","year":"2013","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.neuint.2019.104583_bib25","first-page":"201","volume":"vol. 122","author":"Ghosal","year":"2013"},{"key":"10.1016\/j.neuint.2019.104583_bib26","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites","volume":"7","author":"Goke","year":"1995","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2019.104583_bib27","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications","volume":"94","author":"Goldberg","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuint.2019.104583_bib28","first-page":"143","volume":"vol. 33","author":"Green","year":"2019"},{"key":"10.1016\/j.neuint.2019.104583_bib29","first-page":"117","volume":"vol. 7","author":"Harada","year":"2003"},{"key":"10.1016\/j.neuint.2019.104583_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-7091-0643-3_6","article-title":"Animal models of Parkinson's disease in rodents induced by toxins: an update","author":"Hirsch","year":"2003","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.neuint.2019.104583_bib31","first-page":"547","volume":"vol. 27","author":"Holst","year":"2011"},{"key":"10.1016\/j.neuint.2019.104583_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuint.2019.104583_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","article-title":"Glucagon-like peptide-1 inhibits LPS-induced IL-1 beta production in cultured rat astrocytes","volume":"55","author":"Iwai","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuint.2019.104583_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson' s disease by increasing expression of BNDF","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2019.104583_bib35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1177\/0963689717721234","article-title":"A new treatment strategy for Parkinson's disease through the gut\u2013brain Axis: the glucagon-like peptide-1 receptor pathway","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1016\/j.neuint.2019.104583_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2009.09.103","article-title":"Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease","volume":"1306","author":"Kim","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2019.104583_bib37","doi-asserted-by":"crossref","first-page":"10470","DOI":"10.1523\/JNEUROSCI.22-23-10470.2002","article-title":"The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness","volume":"22","author":"Kinzig","year":"2002","journal-title":"J. Neurosci. : The Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuint.2019.104583_bib38","first-page":"660","volume":"vol. 33","author":"Lang","year":"2018"},{"key":"10.1016\/j.neuint.2019.104583_bib39","first-page":"271","article-title":"Astaxanthin protects against MPTP\/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro Food and chemical toxicology","volume":"49","author":"Lee","year":"2011","journal-title":"An Int. J. Pub. British Ind. Biol. Res. Assoc."},{"key":"10.1016\/j.neuint.2019.104583_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.neuint.2019.104583_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00125-007-0886-7","article-title":"The mechanisms of alloxan- and streptozotocin-induced diabetes","volume":"51","author":"Lenzen","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuint.2019.104583_bib42","first-page":"326","volume":"vol. 11","author":"Li","year":"2016"},{"key":"10.1016\/j.neuint.2019.104583_bib43","first-page":"1285","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"vol. 106","author":"Li","year":"2009"},{"key":"10.1016\/j.neuint.2019.104583_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bbrc.2010.07.033","article-title":"Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells","volume":"399","author":"Maj","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuint.2019.104583_bib45","series-title":"The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review Oxidative Medicine and Cellular Longevity 2016","author":"Manoharan","year":"2016"},{"key":"10.1016\/j.neuint.2019.104583_bib46","series-title":"Highway Safety Manual Vol 1","author":"Manual NRCTRBTFoDotHS","year":"2010"},{"key":"10.1016\/j.neuint.2019.104583_bib47","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.freeradbiomed.2007.08.001","article-title":"CR-6 protects glutathione peroxidase activity in experimental diabetes","volume":"43","author":"Miranda","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuint.2019.104583_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","article-title":"Glucagon-like peptide-1 and the central\/peripheral nervous system","volume":"28","author":"Muscogiuri","year":"2017","journal-title":"Crosstalk in Diabetes Trends in endocrinology and metabolism: TEM (Trends Endocrinol. Metab.)"},{"key":"10.1016\/j.neuint.2019.104583_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12035-013-8483-x","article-title":"The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease","volume":"49","author":"Niranjan","year":"2014","journal-title":"Focus on Astrocytes Mol. Neurobiol."},{"key":"10.1016\/j.neuint.2019.104583_bib50","first-page":"1583","article-title":"The prevalence of Parkinson's disease","volume":"29","author":"Pringsheim","year":"2014","journal-title":"A systematic review and meta\u2010analysis Movement disorders"},{"key":"10.1016\/j.neuint.2019.104583_bib51","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuint.2019.104583_bib52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.freeradbiomed.2010.12.006","article-title":"Oxidative stress, insulin signaling, and diabetes","volume":"50","author":"Rains","year":"2011","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.neuint.2019.104583_bib53","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1476-5381.2012.02100.x","article-title":"Retracted: exendin\u20104 reverts behavioural and neurochemical dysfunction in a pre\u2010motor rodent model of Parkinson's disease with noradrenergic deficit","volume":"167","author":"Rampersaud","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2019.104583_bib54","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/en.2012-1786","article-title":"Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats","volume":"154","author":"Romani-Perez","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuint.2019.104583_bib55","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1002\/mds.22049","article-title":"Levodopa unresponsive symptoms in Parkinson disease Movement disorders","volume":"23","author":"Sethi","year":"2008","journal-title":"Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.neuint.2019.104583_bib56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra\u2010pancreatic effects of GLP\u20101 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems Diabetes","volume":"16","author":"Seufert","year":"2014","journal-title":"Obes. Metab."},{"key":"10.1016\/j.neuint.2019.104583_bib57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","volume":"128","author":"Sharma","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2019.104583_bib58","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3892\/mmr.2016.5573","article-title":"Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine\/probenecid-induced Parkinson's disease in mice","volume":"14","author":"Shi","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuint.2019.104583_bib59","first-page":"240","article-title":"Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors European","volume":"96","author":"Spielman","year":"2017","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.neuint.2019.104583_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.nlm.2011.01.004","article-title":"Bidirectional metabolic regulation of neurocognitive function","volume":"96","author":"Stranahan","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuint.2019.104583_bib61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.33549\/physiolres.930111","article-title":"The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas","volume":"50","author":"Szkudelski","year":"2001","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuint.2019.104583_bib62","first-page":"323","volume":"vol. 37","author":"Tan","year":"2009"},{"key":"10.1016\/j.neuint.2019.104583_bib63","first-page":"510","volume":"vol. 37","author":"Tansey","year":"2010"},{"key":"10.1016\/j.neuint.2019.104583_bib64","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuint.2012.12.016","article-title":"Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease","volume":"62","author":"Taylor","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2019.104583_bib65","first-page":"8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1","volume":"vol. 89","author":"Thorens","year":"1992"},{"key":"10.1016\/j.neuint.2019.104583_bib66","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009365","article-title":"Programmed cell death in Parkinson's disease","volume":"2","author":"Venderova","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuint.2019.104583_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J. Clin. Investig."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018619304371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018619304371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:49:13Z","timestamp":1759312153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018619304371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":67,"alternative-id":["S0197018619304371"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2019.104583","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2019.104583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104583"}}